Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,057.00.
Akash Tewari’s rating is based on several factors that indicate a positive outlook for Eli Lilly & Co. Despite a recent stock decline due to CVS Caremark’s decision to favor a competitor’s product, Tewari believes the impact on Eli Lilly’s market share will be limited. The analyst highlights that the affected patient pool is relatively small and remains confident in the company’s long-term growth prospects.
Furthermore, Tewari points out that Eli Lilly has reiterated its revenue guidance for 2025, suggesting a sustainable growth trajectory. The company’s strong performance in key products like Mounjaro, along with its strategic positioning in the obesity market, supports the Buy rating. Tewari also emphasizes that Eli Lilly’s pricing strategies and potential economies of scale could mitigate competitive pressures, reinforcing the company’s robust market position.
Tewari covers the Healthcare sector, focusing on stocks such as Pfizer, Eli Lilly & Co, and Jazz Pharmaceuticals. According to TipRanks, Tewari has an average return of 3.7% and a 40.36% success rate on recommended stocks.